A year ago, David Cameron and his wife Samantha were listening to an interview on Times UK that would change the former prime minister’s life. Nick Jones, founder of the Soho House empire, was describing how a routine prostate test in 2022 had detected his cancer early enough for treatment. Samantha turned to her husband and told him he should ask his GP about the same test. He did — and that simple suggestion set off a chain of events that led to a deeply personal diagnosis and a new public mission.
Sitting in his House of Lords office, Cameron recalls the unsettling progression of his results. The PSA test came back alarmingly high. The MRI scan showed suspicious dark marks. And then the biopsy delivered the words he had been dreading from the moment the doctor opened his mouth: prostate cancer. As he describes it, you hope every stage is just a false alarm until the moment reality becomes unavoidable.
Although Cameron admits he dislikes talking about intimate health issues, he feels he has an obligation to speak up. Men, he says, are notoriously reluctant to discuss their health, particularly when it involves something as sensitive as the prostate. But after what he went through, he believes staying silent would be wrong. His experience has convinced him to publicly support Prostate Cancer Research’s call for targeted screening for high-risk men, arguing that new technologies — from more precise MRI scans to improved genetic assessments — have shifted the balance in favour of wider testing.
Cameron’s urgency is partly shaped by personal loss. His older brother Alexander died of pancreatic cancer at the same age Cameron is now, a fact that left him unwilling to “watch and wait.” Faced with a decision between surveillance and treatment, he chose to act quickly. He opted for a focal therapy approach, a less invasive procedure using electric pulses to destroy cancerous cells. The follow-up scan, he remembers, felt like receiving a “bomb damage assessment” — a precise strike that removed the dangerous tissue while sparing the vital nerves around it.
His story comes amid a broader debate within the medical community. While advocates such as Chris Hoy, Nick Jones, and even former prime minister Rishi Sunak are calling for national screening, some experts warn that mass testing could lead to unnecessary treatments and side-effects for cancers that would never have become life-threatening. Millions of men have prostate cancer without ever dying from it, and large-scale screening risks identifying cases that might never require intervention.
Yet Cameron argues the landscape is changing. A major new trial has begun in the UK to examine whether combining PSA testing with more advanced imaging and genetic analysis improves outcomes. A recent European study already suggests long-term screening can reduce prostate cancer deaths by 13 per cent. With improved therapies producing fewer side-effects and high-risk groups showing clearer benefits, he believes the case for revisiting national policy is stronger than ever.
For Cameron, the issue is no longer abstract. It is personal and urgent, and it has left him determined to add his voice to those pushing for reform. His message is straightforward: testing helped him catch his cancer early, and he believes many more lives could be saved if the UK is willing to rethink how it approaches this silent and deadly disease.
